Major US-Backed HIV Vaccine Trial Ends In Failure

NBC News reports:

The only HIV vaccine in a late-stage trial has failed, researchers announced Wednesday, dealing a significant blow to the effort to control the global HIV epidemic and adding to a decadeslong roster of failed attempts.

Known as Mosaico, the trial was the product of a public-private partnership including the U.S. government and the pharmaceutical giant Janssen. It was run out of eight nations in Europe and the Americas, including the U.S., starting in 2019. Researchers enrolled nearly 3,900 men who have sex with men and transgender people, all deemed at substantial risk of HIV.

The leaders of the study decided to discontinue the mammoth research effort after an independent data and safety monitoring board reviewed the trial’s findings and saw no evidence the vaccine lowered participants’ rate of HIV acquisition.

Read the full article.

The only #HIV vaccine in a late-stage trial has failed, dealing a significant blow to the effort to control the global HIV epidemic and adding to a decadeslong roster of failed attempts, @mattlavietes and I report for @NBCNews @NBCOUT. https://t.co/AVdEHI34Gf

— Benjamin Ryan (@benryanwriter) January 18, 2023